Jonathan Kaufman, MD
Medical Oncology · Atlanta, GANPI 1093819138
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (59.7%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. 17 manufacturers reported payments, led by Sanofi at 30.9% of the total. Reporting peaked in 2019 at $32,735 and has fallen 89.8% since, to $3,327 in 2025. Among medical oncology clinicians in GA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 92 payments — averaging $797.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$23K
- Janssen Global Services, LLC$14K
- Bristol Myers Squibb$7K
- Amgen$6K
- Takeda Pharmaceuticals U.S.A., Inc.$6K
- AbbVie$5K
- plus $13K from 11 others
Across 825 payments — averaging $9274.09 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$2.6M
- Janssen Research & Development, LLC$2M
- Takeda Pharmaceuticals U.S.A., Inc.$677K
- Pfizer$435K
- Amgen$381K
- Novartis$354K
- plus $1.2M from 12 others
What the payments were for
- Consulting fees$43,80060%
- Grants$3420%
- Travel & lodging$26,12536%
- Food & beverage$3,0404%
- Education$430%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 19 | $22,650 |
| Janssen Global Services, LLC | 7 | $14,045 |
| Bristol Myers Squibb | 12 | $6,864 |
| Amgen | 8 | $6,118 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $5,677 |
| AbbVie | 3 | $5,039 |
| Incyte Corporation | 2 | $4,920 |
| E.r. Squibb & Sons, L.L.C. | 3 | $2,433 |
| Gilead | 2 | $2,160 |
| Genentech, Inc. | 2 | $1,850 |
| Johnson & Johnson | 18 | $852 |
| Pfizer | 3 | $151 |
| Adaptive Biotechnologies Corporation | 2 | $150 |
| GSK | 1 | $125 |
| TG Therapeutics, Inc. | 1 | $120 |
| AstraZeneca | 2 | $118 |
| Legend Biotech USA Inc. | 2 | $79 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$73,350 in reported general payments places this provider in the 90th percentile of 68 medical oncology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PomalystPomalidomide | 134 | $3,138,835 |
| RevlimidLenalidomide | 156 | $2,735,930 |
| Lenalidomide | 190 | $2,643,844 |
| NinlaroIxazomib Citrate | 64 | $800,201 |
| XpovioSelinexor | 15 | $455,598 |
| BrukinsaZanubrutinib | 30 | $407,346 |
| ImbruvicaIbrutinib | 22 | $349,053 |
| VenclextaVenetoclax | 23 | $300,385 |
| CalquenceAcalabrutinib Maleate | 24 | $254,686 |
| ZarxioFilgrastim-Sndz | 34 | $85,102 |
| EliquisApixaban | 40 | $30,162 |
| Xtampza ErOxycodone Myristate | 13 | $15,324 |
| ValacyclovirValacyclovir Hcl | 201 | $11,260 |
| Entecavir | 42 | $2,305 |
| Oxycodone Hcl | 64 | $821 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| E.r. Squibb & Sons, L.L.C.Pomalyst | $2,433 | $3,138,835134 claims |
| Bristol Myers SquibbRevlimid | $6,864 | $2,735,930156 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Ninlaro | $5,677 | $800,20164 claims |
| AbbVieVenclexta | $5,039 | $300,38523 claims |
| AstraZenecaCalquence | $118 | $254,68624 claims |
| PfizerEliquis | $151 | $30,16240 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 68 medical oncology providers in Georgia.
Other medical oncology in Atlanta
- Nabil SabaAtlanta$225K
- Suresh RamalingamAtlanta$75K
- Ragini KudchadkarAtlanta$69K
- Nisha JosephAtlanta$50K
- Eyal MeiriAtlanta$39K
- Erin DunbarAtlanta$35K
- Olumide GbolahanAtlanta$32K
- Bradley CarthonAtlanta$31K
- Joseph MaakaronAtlanta$29K
- Ruth SacksAtlanta$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.